• 1
    Krystal J, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-41.
  • 2
    Duman R, Aghajanian GK. Synaptic dysfunction in depression: novel therapeutic targets. Science 2012;338:68-72.
  • 3
    Li N, Lee BY, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64.
  • 4
    Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27:11496-500.
  • 5
    Dwyer JM, Duman RS. Unpublished data.
  • 6
    Liu R-J, Fuchikami M, Dwyer JM et al. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology (in press).
  • 7
    Drevets W, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-8.
  • 8
    Voleti B, Navarria A, Liu R-J et al. Scopolamine rapidly increases mTORC1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry (in press).
  • 9
    Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013;31:105-14.
  • 10
    Chaudhury D, Walsh JJ, Friedman AK et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013;493:532-6.
  • 11
    Chung K, Wallace J, Kim SY et al. Structural and molecular interrogation of intact biological systems. Nature 2013;497:332-7.